Neurogene Stock Performance
| NGNE Stock | 19.12 0.81 4.42% |
The company secures a Beta (Market Risk) of 2.31, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neurogene will likely underperform. At this point, Neurogene has a negative expected return of -0.64%. Please make sure to verify Neurogene's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Neurogene performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Neurogene has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (3.58) | Five Day Return 4.27 | Year To Date Return (9.18) | Ten Year Return (91.70) | All Time Return (92.34) |
Last Split Factor 1:4 | Last Split Date 2023-12-19 |
1 | Is Neurogene Inc. stock cheap by valuation metrics - July 2025 Sector Moves Verified Stock Trade Ideas - newser.com | 11/18/2025 |
2 | Companies Like Neurogene Are In A Position To Invest In Growth | 11/26/2025 |
3 | Neurogene Earnings Notes - Trefis | 12/15/2025 |
4 | Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference | 01/05/2026 |
5 | Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome | 01/12/2026 |
| Begin Period Cash Flow | 148.7 M | |
| Total Cashflows From Investing Activities | -125.3 M |
Neurogene | Build AI portfolio with Neurogene Stock |
Neurogene Relative Risk vs. Return Landscape
If you would invest 3,102 in Neurogene on October 28, 2025 and sell it today you would lose (1,190) from holding Neurogene or give up 38.36% of portfolio value over 90 days. Neurogene is currently does not generate positive expected returns and assumes 5.1323% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Neurogene, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurogene Target Price Odds to finish over Current Price
The tendency of Neurogene Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 19.12 | 90 days | 19.12 | about 77.04 |
Based on a normal probability distribution, the odds of Neurogene to move above the current price in 90 days from now is about 77.04 (This Neurogene probability density function shows the probability of Neurogene Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.31 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Neurogene will likely underperform. Additionally Neurogene has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Neurogene Price Density |
| Price |
Predictive Modules for Neurogene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neurogene. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Neurogene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neurogene is not an exception. The market had few large corrections towards the Neurogene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neurogene, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neurogene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.89 | |
β | Beta against Dow Jones | 2.31 | |
σ | Overall volatility | 5.08 | |
Ir | Information ratio | -0.15 |
Neurogene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurogene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurogene can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurogene generated a negative expected return over the last 90 days | |
| Neurogene has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 925 K. Net Loss for the year was (75.14 M) with loss before overhead, payroll, taxes, and interest of (69.72 M). | |
| Neurogene generates negative cash flow from operations | |
| Neurogene has a frail financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome |
Neurogene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neurogene Stock often depends not only on the future outlook of the current and potential Neurogene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurogene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 17.6 M | |
| Cash And Short Term Investments | 312.4 M |
Neurogene Fundamentals Growth
Neurogene Stock prices reflect investors' perceptions of the future prospects and financial health of Neurogene, and Neurogene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurogene Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 29.48 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 313.77 X | ||||
| Revenue | 925 K | ||||
| Gross Profit | (69.72 M) | ||||
| EBITDA | (71.89 M) | ||||
| Net Income | (75.14 M) | ||||
| Total Debt | 12.43 M | ||||
| Book Value Per Share | 17.97 X | ||||
| Cash Flow From Operations | (70.6 M) | ||||
| Earnings Per Share | (4.10) X | ||||
| Market Capitalization | 283.62 M | ||||
| Total Asset | 335.73 M | ||||
| Retained Earnings | (262.3 M) | ||||
| Working Capital | 300.77 M | ||||
About Neurogene Performance
By analyzing Neurogene's fundamental ratios, stakeholders can gain valuable insights into Neurogene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neurogene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurogene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 14.87 | 13.22 | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Neurogene performance evaluation
Checking the ongoing alerts about Neurogene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurogene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurogene generated a negative expected return over the last 90 days | |
| Neurogene has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 925 K. Net Loss for the year was (75.14 M) with loss before overhead, payroll, taxes, and interest of (69.72 M). | |
| Neurogene generates negative cash flow from operations | |
| Neurogene has a frail financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome |
- Analyzing Neurogene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurogene's stock is overvalued or undervalued compared to its peers.
- Examining Neurogene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurogene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurogene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurogene's stock. These opinions can provide insight into Neurogene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neurogene Stock analysis
When running Neurogene's price analysis, check to measure Neurogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurogene is operating at the current time. Most of Neurogene's value examination focuses on studying past and present price action to predict the probability of Neurogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurogene's price. Additionally, you may evaluate how the addition of Neurogene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |